The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy.
David J. K. P. Pfister
No relevant relationships to disclose
Daniel Porres
No relevant relationships to disclose
Charlotte Piper
No relevant relationships to disclose
Axel S. Merseburger
No relevant relationships to disclose
Theodor Klotz
No relevant relationships to disclose
Axel Heidenreich
No relevant relationships to disclose